In Blow To University, Panel Upholds Prodrug Patent Cancellation
WASHINGTON, D.C. — The Federal Circuit U.S. Court of Appeals on March 6 said the Patent Trial and Appeal Board got it right when declaring various claims of a patented phosphoramidate...To view the full article, register now.
Already a subscriber? Click here to view full article